New drug cocktail aims to tackle tough gut cancers

NCT ID NCT07233850

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe and shrinks tumors. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SSGJ-706 (an experimental drug) plus chemotherapy (oxaliplatin, capecitabine) and sometimes bevacizumab
What this could lead to
If successful, this could point toward a new combination treatment option for people with advanced gastrointestinal cancers that are hard to treat.
What could go wrong
This is an early Phase 2 trial, so it is not yet proven to work. The added drug may increase side effects without improving outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.